Anand Mehta
Family Medicine · Marietta, GANPI 1629365283
Payments from drug & device makers
Across 181 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$261
- AstraZeneca$159
- Amgen$112
- AbbVie$92
- Takeda Pharmaceuticals U.S.A., Inc.$89
- plus $558 from 16 others
What the payments were for
- Food & beverage$2,784100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 106 | $1,524 |
| Lilly USA, LLC | 15 | $261 |
| AstraZeneca | 9 | $159 |
| Amgen | 6 | $112 |
| AbbVie(2 entities) | 6 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $89 |
| Antares Pharma, Inc. | 4 | $74 |
| Pfizer | 5 | $72 |
| Globus Medical | 2 | $72 |
| Esperion Therapeutics, Inc. | 4 | $70 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $43 |
| GSK | 2 | $34 |
| Exact Sciences | 2 | $31 |
| Abbott | 1 | $22 |
| UCB, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,796 in reported general payments places this provider in the 75th percentile of 3,111 family medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 24 | $119,205 |
| OzempicSemaglutide | 38 | $48,192 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $16,184 |
| Memantine Hcl ErMemantine Hcl | 16 | $1,087 |
| Tamsulosin Hcl | 32 | $418 |
| Celecoxib | 15 | $366 |
| Zolpidem Tartrate | 41 | $350 |
| Sertraline Hcl | 57 | $324 |
| Metoprolol Succinate | 30 | $313 |
| Carbamazepine | 14 | $243 |
| Gabapentin | 23 | $232 |
| Levothyroxine Sodium | 26 | $220 |
| Benztropine Mesylate | 15 | $195 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 15 | $180 |
| Omeprazole | 16 | $160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $18 | $119,20524 claims |
| Novo NordiskOzempic | $1,524 | $48,19238 claims |
| GSKTrelegy Ellipta | $34 | $16,18418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Marietta
- Cedrice DavisMarietta$621K
- Irshad SyedMarietta$118K
- Mitzi RubinMarietta$103K
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.